Top

Clinical Drug Investigation

Published in:

01-05-2009 | Original Research Article

Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain

Preliminary Findings from a Three-Way Randomized, Crossover Study

Authors: Chui Chong, Prof Stephan A. Schug, Madhu Page-Sharp, Barry Jenkins, Kenneth F. Ilett

Published in: Clinical Drug Investigation | Issue 5/2009

Abstract

Background and objective: Enterally administered low-dose ketamine is being used increasingly to treat pain states. However, suitable oral or sublingual formulations are not available. The objective of the study was to develop a lozenge formulation of ketamine for use in patients with neuropathic pain, and to investigate its storage stability and bioavailability after oral or sublingual administration.

Methods: A lozenge containing 25mg of ketamine was formulated and manufactured in a hospital pharmacy setting. Stability was assessed by high-performance liquid chromatography (HPLC) during storage at 25°C or 2–8°C for up to 14 weeks. Bioavailability after both oral and sublingual administration was evaluated in six patients with chronic neuropathic pain. Ketamine and its metabolite norketamine in plasma were measured by HPLC.

Results: The lozenge formulation was chemically stable for at least 14 weeks. Oral and sublingual bioavailabilities [median (interquartile range)] were 24% (17–27%) and 24% (19–49%), respectively. There was substantial metabolism to norketamine for both routes. The mean norketamine/ketamine area under the plasma concentration-time curve from baseline to 8 hours ratios were 5 and 2.1 after oral or sublingual administration, respectively.

Conclusion: The ketamine lozenge showed acceptable storage stability. Bioavailability was sufficiently high and reproducible to support its use in routine pain management. There was extensive first-pass conversion to norketamine. Efficacy studies are warranted to evaluate sublingual and oral administration of our new lozenge formulation of ketamine in patients with chronic pain states. Investigation of the role of the metabolite norketamine, which is also an NMDA receptor antagonist, is particularly important because this may contribute significantly to clinical efficacy.

Reich DL, Silvay G. Ketamine: an update on the 1st 25 years of clinical experience. Can J Anaesth 1989; 36: 186–97PubMedCrossRef

Walker SM, Cousins MJ. Reduction in hyperalgesia and intrathecal morphine requirements by low-dose ketamine infusion. J Pain Symptom Manage 1997; 14: 129–33PubMedCrossRef

Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003; 97: 1730–9PubMedCrossRef

Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage 2000; 19: S21–5PubMedCrossRef

Price DD, Mayer DJ, Mao J, et al. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage 2000; 19: S7–11PubMedCrossRef

Sator-Katzenschlager S, Deusch E, Maier P, et al. The long-term antinociceptive effect of intrathecal S(+)-ketamine in a patient with established morphine tolerance. Anesth Analg 2001; 93: 1032–4PubMedCrossRef

Eilers H, Philip LA, Bickler PE, et al. The reversal of fentanyl-induced tolerance by administration of “small-dose” ketamine. Anesth Analg 2001; 93: 213–4PubMedCrossRef

Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004; 99: 482–95PubMedCrossRef

Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982; 71: 539–42PubMedCrossRef

10.

Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30: 853–8PubMedCrossRef

11.

Kannan TR, Saxena A, Bhatnagar S, et al. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002; 23: 60–5PubMedCrossRef

12.

Fitzgibbon EJ, Hall P, Schroder C, et al. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 2002; 23: 165–70PubMedCrossRef

13.

Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. J Pain Symptom Manage 1999; 17: 384–6PubMedCrossRef

14.

Gross AS, Nicolay A, Eschalier A. Simultaneous analysis of ketamine and bupivacaine in plasma by high-performance liquid chromatography. J Chromatog B 1999; 728: 107–15CrossRef

15.

Hijazi Y, Bolon M, Boulieu R. Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples. Clin Chem 2001; 47: 1713–5PubMed

16.

Thomann P. Non-compartmental analysis methods manual. In: Heinzel G, Woloszcak R, Thomann P, editors. TopFit 2.0 pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer, 1993: 5–66

17.

Heinzel G, Tanswell P. Compartmental analysis methods manual. In: Heinzel G, Woloszcak R, Thomann P, editors. Topfit 2.0 pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer, 1993: 5–140

18.

Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003; 24: 37–43PubMedCrossRef

19.

Hijazi Y, Bodonian C, Salord F, et al. Pharmacokinetic-pharmacodynamic modelling of ketamine in six neuro-traumatised intensive care patients. Clin Drug Invest 2003; 23: 605–9CrossRef

20.

Yanagihara Y, Ohtani M, Matsumoto M, et al. Preparation of ketamine tablets for treatment of patients with neuropathic pain. Yakugaku Zasshi 1999; 119: 980–7PubMed

21.

Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 1981; 53: 805–10PubMedCrossRef

22.

Ebert B, Mikkelsen S, Thorkildsen C, et al. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333: 99–104PubMedCrossRef

23.

Shimoyama M, Shimoyama N, Gorman AL, et al. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 1999; 81: 85–93PubMedCrossRef

24.

Edwards SR, Mather LE. Tissue uptake of ketamine and norketamine enantiomers in the rat: indirect evidence for extrahepatic metabolic inversion. Life Sci 2001; 69: 2051–66PubMedCrossRef

25.

Bushnell TG, Craig J. Response of chronic neuropathic pain syndromes to ketamine: a role for norketamine [letter]? Pain 1995; 60: 115PubMedCrossRef

Title: Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain
Preliminary Findings from a Three-Way Randomized, Crossover Study
Authors: Chui Chong
Prof Stephan A. Schug
Madhu Page-Sharp
Barry Jenkins
Kenneth F. Ilett
Publication date: 01-05-2009
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 5/2009
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200929050-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain

Preliminary Findings from a Three-Way Randomized, Crossover Study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Effect of Ivabradine, a Novel Antianginal Agent, on Driving Performance

Pharmacokinetics of Two 6-Day Frovatriptan Dosing Regimens Used for the Short-Term Prevention of Menstrual Migraine

HairMax LaserComb® Laser Phototherapy Device in the Treatment of Male Androgenetic Alopecia

RETRACTED ARTICLE: Anti-Fracture Efficacy of Risedronic Acid in Men

Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4mg/day to Solifenacin Treatment

Combination Therapy with Candesartan Cilexetil 32mg and Hydrochlorothiazide 25mg Provides the Full Additive Antihypertensive Effect of the Components